Product logins

Find logins to all Clarivate products below.


Electrophysiology Mapping and Ablation Devices | Market Insights | Latin America | 2022

The Latin American EP mapping and ablation device market will experience strong growth through 2030, particularly in the diagnostic and ablation catheter segments, owing largely to expanding ablation volumes. However, the COVID-19 global pandemic had an impact on the Latin American EP mapping and ablation device market, resulting in lost procedure volumes in the short term followed by a period of recovery.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for EP mapping and ablation devices in the Latin American region across an 11-year period.

Related Medtech Insights Reports

Report
Interventional Cardiology Devices – Market Insights – Latin America
The Latin American IC device market will see strong growth over the forecast period, driven by a rising patient population, the introduction of next-generation devices, and the expanding adoption…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2034, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Latin America (Supplemental)
The Latin American EP mapping and ablation device market will experience strong growth through 2033, driven by the increasing prevalence of cardiac arrhythmia in Latin American countries, improved…
Report
Aesthetic Injectables – Market Insights – Latin America
The Latin American aesthetic injectable market is expected to experience rapid growth through 2034. This expansion will be driven by product development and differentiation efforts from market…
Report
Biosurgical Agents – Market Insights – Latin America (Supplemental)
The biosurgical agent market in Latin America will observe modest growth through 2033, primarily driven by the increasing number of procedures utilizing biosurgical agents, combined with favorable…